Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
21-40 of 2,120 trials

Febrile Neutropenia: SAFE Study on Short Antibiotic Treatment

We are studying whether stopping antibiotics after 3 days is as safe as continuing them longer for patients with febrile neutropenia. This research aims to find a potentially safer treatment approach for hematology patients.

Febrile Neutropenia>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

Risankizumab for Moderate to Severe Plaque Psoriasis in Children and Teens

We are studying the long-term safety and effectiveness of risankizumab in children and teens aged 6 to 17 with moderate to severe plaque psoriasis. This follows their participation in a previous study to see how well the treatment works over time.

Plaque Psoriasis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyDermatology

Cardiac Surgery: Vasopressin vs. Norepinephrine

We are comparing two medications to see which better protects kidney function and reduces complications in patients at risk during cardiac surgery. This study aims to improve outcomes for those undergoing surgery with heart-lung machines.

Vasoplegic Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal MedicineNephrologyOtolaryngology

Anemia in Low-Risk Myelodysplastic Syndrome: Luspatercept vs Epoetin Alfa

We are comparing a new treatment, luspatercept, with a standard treatment, epoetin alfa, for patients with low-risk myelodysplastic syndrome who do not need blood transfusions. The goal is to see which treatment better helps manage anemia.

Myelodysplastic Syndrome (MDS)>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

HER2 Status in Solid Tumors: [68Ga]Ga-ABY-025 PET Study

We are investigating a new PET imaging method to measure HER2 status in patients with low HER2 breast cancer. This study aims to see if it can help better identify tumor characteristics and improve treatment planning.

Breast CancerGastro-esophageal Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Multiple Myeloma: Isatuximab and Lenalidomide Study

We are comparing two treatment plans for newly diagnosed low-risk multiple myeloma patients to see which is more effective in reducing cancer cells. This study aims to understand the best approach for long-term patient health.

Multiple Myeloma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Marstacimab for Severe Hemophilia A and B

We are studying the long-term safety and effectiveness of marstacimab in people aged 1 to 75 with severe hemophilia A or B, with or without inhibitors. This research aims to improve treatment options for managing this condition.

Haemophilia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Marstacimab for Pediatric Hemophilia

We are studying a new treatment for children with severe hemophilia A or B to see if it is safer and more effective than standard care. This trial includes participants with or without inhibitors.

Haemophilia1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Type 1 Diabetes: Frexalimab Treatment Study

We are studying a new medication, frexalimab, to see if it helps preserve insulin production in young people with newly diagnosed type 1 diabetes. Participants will receive either the medication or a placebo while continuing their insulin therapy.

Type 1 Diabetes1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesEndocrinologyInternal Medicine

Advanced Breast Cancer: ARV-471 vs Fulvestrant

We are studying a new medication, ARV-471, to see if it works better than fulvestrant for patients with advanced estrogen receptor-positive, HER2-negative breast cancer. This trial is for those whose cancer has progressed after prior treatments.

Advanced Breast CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

BOTOX for Masseter Muscle Prominence

We are studying whether BOTOX injections can help reduce the prominence of the masseter muscle in adults. This trial compares BOTOX to a placebo to evaluate its effectiveness and safety.

Masseter Muscle Prominence1-2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementDermatology

Prostate Cancer: Lutetium-177 vs. Standard Treatments

We are comparing a new treatment called Lutetium-177 with standard medications for men with metastatic hormone-sensitive prostate cancer. The goal is to see which option better delays disease progression and improves survival.

Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Individualized Immunotherapy for Early-Stage Hodgkin Lymphoma

We are testing a new personalized treatment using tislelizumab for adults with early-stage unfavorable classical Hodgkin lymphoma. The goal is to see if this approach improves treatment outcomes and is safe for patients.

Early-Stage Unfavorable Classical Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Waldenström’s Macroglobulinemia: Venetoclax with Rituximab

We are studying whether the combination of Venetoclax and Rituximab is more effective than standard treatments for patients with Waldenström’s Macroglobulinemia. This research aims to find better options for managing this condition.

Waldenström's Macroglobulinemia1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Tranexamic Acid for Spontaneous Brain Bleeding

We are studying whether tranexamic acid can help reduce early deaths in patients with spontaneous intracerebral hemorrhage. Additionally, we will look at its effects on recovery six months later.

Stroke3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesNeurology

Prostate Medication and Gut Health Study

We are investigating how prostate treatments affect gut bacteria and how these bacteria may influence treatment responses in men with BPH and prostate cancer.

Prostate CancerBenign Prostate Hyperplasia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineUrology

Hepatocellular Carcinoma: New Vaccine with Atezolizumab and Bevacizumab

We are studying a new cancer vaccine combined with two existing treatments for patients with unresectable liver cancer. The goal is to see if this combination improves survival and quality of life.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHepatologyInternal MedicineOncology

Immunotherapy for Early dMMR Rectal Cancer

We are studying the effects of nivolumab and ipilimumab in patients with stage 1-3 dMMR rectal cancer. The goal is to see how effective and tolerable this treatment is.

Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Duchenne Muscular Dystrophy: SQY51 Treatment Study

We are studying the safety and effects of a new treatment called SQY51 in children and adults with Duchenne Muscular Dystrophy. The goal is to see how it impacts muscle function and overall well-being.

Duchenne Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOrthopedics and Traumatology

Post-Cardiac Arrest Shock: High-Dose Vitamin C Study

We are investigating whether early intravenous high-dose vitamin C can help patients who have suffered a cardiac arrest and are in shock. The study aims to see if this treatment reduces the need for blood pressure support and improves survival and recovery.

Cardiac Arrest6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine